EP0695285A1 - Stereospecific synthesis of polyene compounds - Google Patents

Stereospecific synthesis of polyene compounds

Info

Publication number
EP0695285A1
EP0695285A1 EP94915855A EP94915855A EP0695285A1 EP 0695285 A1 EP0695285 A1 EP 0695285A1 EP 94915855 A EP94915855 A EP 94915855A EP 94915855 A EP94915855 A EP 94915855A EP 0695285 A1 EP0695285 A1 EP 0695285A1
Authority
EP
European Patent Office
Prior art keywords
carbons
acid
lower alkyl
hydrogen
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94915855A
Other languages
German (de)
French (fr)
Other versions
EP0695285A4 (en
Inventor
Steven K. White
Chan Kou Hwang
David T. Winn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Ligand Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ligand Pharmaceuticals Inc filed Critical Ligand Pharmaceuticals Inc
Priority to EP97122793A priority Critical patent/EP0839788A1/en
Publication of EP0695285A1 publication Critical patent/EP0695285A1/en
Publication of EP0695285A4 publication Critical patent/EP0695285A4/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/20Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/60Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • the present invention relates to the stereospecific synthesis of polyene compounds, such as eicosanoids and retinoids.
  • polyene compounds such as eicosanoids and retinoids.
  • a cis olefin is generated via a lactol ring opening with complete retention of double bond configuration.
  • an extended conjugated olefinic chain is present and important for biological effects.
  • Many of the compounds within the arachidonic acid cascade are important modulators of inflammation.
  • leukotriene 34 has been detected in fluid from involved tissue in rheumatoid arthritis, gout, psoriasis and ulcerative colitis. (Bhattacherjee et al . , Ann . N. Y. Acad. Sci . , 524:307 (1984)).
  • the absolute stereochemistry of the olefinic series is often an important feature of these compounds.
  • retinoid members of the steroid/thyroid superfamily of receptors are responsive to compounds referred to as retinoids, which include retinoic acid, retinol (vitamin A) , and a series of natural and synthetic derivatives which have been found to exert profound effects on development and differentiation in a wide variety of systems.
  • retinoids include retinoic acid, retinol (vitamin A)
  • vitamin A vitamin A
  • Novel members of the steroid/thyroid superfamily of receptors have been identified which are not responsive to retinoic acid, • called retinoid X receptors.
  • 9-o ' s-retinoic acid has been demonstrated to have affinity for retinoid X receptors (Heyman et al., Cell, 68:397 (1992)), and other retinoids having 9-10 cis olefin geometry have been found to selectively activate retinoid X receptors.
  • R 1 represents a lower or branched alkyl having 1-12 carbons, or phenyl, and can be methyl only if R 2 is hydrogen or a lower alkyl having 1- 8 carbons;
  • R 2 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen, or R 1 and R 2 taken together form a phenyl, cyclohexyl, or cyclopentyl ring;
  • R 4 represents hydrogen, a lower alkyl having 1-8 carbons, or a halogen
  • R 5 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen.
  • R 1 represents a lower or branched alkyl having 1-12 carbons, or phenyl, and can be methyl only if R 2 is hydrogen or a lower alkyl having 1- 8 carbons;
  • R 2 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen, or R 1 and R 2 taken together form a phenyl, cyclohexyl, or cyclopentyl ring or one of the following:
  • R 4 represents hydrogen, a lower alkyl having 1-8 carbons, or a halogen
  • Z, Z', Z", and Z' each independently, represent C, S, 0, N, or a pharmaceutically acceptable salt, but not 0 or S if attached by a double bond to another such Z or if attached to another such Z which is 0 or S, and not N if attached by a single bond to another such Z which is N; and the dashed lines in the structures depict optional double bonds.
  • pharmaceutically acceptable salts include but are not limited to: hydrochloric, hydrobromic, hydroiodic, hydrofluoric, sulfuric, citric, maleic, acetic, lactic, nicotinic, succinic, oxalic, phosphoric, malonic, salicylic, phenylacetic, stearic, pyridine, ammonium, piperazine, diethylamine, nicotinamide, formic, urea, sodium, potassium, calcium, magnesium, zinc, lithium, cinnamic, methylamino, methanesulfonic, picric, tartaric, tri- ethylamino, dimethylamino, and tris (hydroxymethyl)amino- methane. Additional pharmaceutically acceptable salts are known to those of skill in the art.
  • the preferred process sequence begins with the use of a commercially available aldehyde ⁇ -cyclocitral I and the well established Reformatsky reaction. (Dugger eta/., ]. Org. Chem., 45:1181 (1980) ; Gedye et al., Can. ). Chem., 53:1943 (1975) ; Cainelli eta/., J.C.S. Perkin I 1597 (1979)). This step constructs the 9-10 olefin bond in the desired cis-orientation, as shown (II) .
  • the second step consists of reduction of the lactone to a protected aldehyde (lactol) which is necessary for chain length extension.
  • lactol protected aldehyde
  • the reduction is achieved with 1 equivalent of diisobutylaluminum hydride and is sensitive toward work-up.
  • Other reducing agents such as lithium aluminum hydride and sodium bis(2-methoxyethoxy)aluminum hydride can give the same product III but in diminished yield.
  • the third step of this sequence involves a unique and novel lactol ring opening under the presence of acid to afford the aldehyde IV. This step constitutes a major advantage over existing syntheses of the aldehyde IV previously reported in the literature.
  • the ring opening is very sensitive to the pKa of the acid, the concentration of the acid, the concentration of the reactant in the solvent, and the temperature of the reaction.
  • the reaction can be run in chlorinated solvents (CHCL 3 , CH 2 CL 2 , C1CH 2 CH 2 C1) , apolar solvents (benzene, toluene) , or coordinating solvents (diethylether, tetrahydrofuran) .
  • the choice of acids includes: para- toluene sulfonic acid, pyridinium hydrochloride, trichloro- or trifluoro-acetic acid, acetic acid, sulfuric acid, nitric acid, tartaric acid, oxalyic acid, and in particular hydrochloric acid.
  • This third step can also be used to achieve the desired stereochemical orientation of olefin bonds for other polyene natural products, such as leukotriene B 4 , dehydroneral, etc., and synthetic analogs. Illustrative examples of such compounds are shown below:
  • the fourth step of this sequence includes the selective formation of the C-ll and C-13 olefin bonds simultaneously.
  • This reaction has been reported in the literature (Kryshtal et al., Izvestiya Akad. Nauk USSR, Seriya Khim., 11:2544 (1990)), but never with better than 5:1 ratio of 13-trans to 13-cis olefin formation.
  • a lithium coupled base in tetrahydrofuran in the presence of a coordinating solvent, such as dimethyl piperidine urea allows the formation of the 11,13-trans- olefin bonds in a greater than 15:1 ratio.
  • solvents including diethyl ether, 1,4-dioxane, t-butyl- methyl ether, dimethyl formamide, dimethyl sulfoxide, methanol, ethanol, benzene, toluene, dichloromethane, chloroform, pyridine, and acetonitrile are less effective for overall yield of the desired 11,13-ditrans olefin product.
  • Other bases e.g., sodium hydride, sodium methoxide, sodium amide, potassium t-butoxide, potassium hydride, potassium di-isopropylamide, lithium diisopropylamide, lithium b/s-trimethylsilylamide
  • bases are less effective than n-butyl lithium.
  • the reaction can be completed at -78°C or up to room temperature.
  • the hydrolysis of the ester V to the acid VI is a standard saponification reaction. We have found that the reaction proceeds better in ethanol than ethanol due to the better solubility in the former solvent.
  • One example of a VI compound is 9-c/s-retinoic acid. 11 - cis and 13 - cis retinoids and other related compounds, as illustrated below, can also be prepared using this process scheme.
  • the oil was slurred up in hexane (500 ml) and cooled to -20°C in the refrigerator.
  • the first crop of solid material was 77 g.
  • the filter cake was rinsed again with THF (2 x 500 ml) and concentrated to an oil with solid. Addition of hexane (300 ml) gave another 54 g of product for a total of 131 g (79%) .
  • reaction solution was cooled and allowed to stir at -78°C for 0.25 hour before the aldehyde (75.4 g, 345 mmol) was added in 50 ml of tetrahydrofuran.
  • the reaction was stirred at -78°C for another 0.5 hours, then quenched by the addition of 200 ml of saturated ammonium chloride solution.
  • the aqueous solution was extracted with diethylether (3 x 500 ml) , and the combined organic extracts washed with brine and dried over magnesium sulfate.
  • the crude reaction products (primarily 9 -cis-13 -trans retinoate and 9, 13-di-c/s-retinoate) were collected by concentration in vacuo to give a red-orange oil.
  • the crude ester was taken up in 100 ml of 20% Et 2 0/Hexane and filtered through 500 g of silica gel (230-400 mesh) which was rinsed with another 700 ml of eluent .
  • the ester was concentrated to an orange oil (100.4 g, 93%) which looked very clean by NMR.
  • the 13 E/Z ratio was > 15:1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Catalysts (AREA)

Abstract

Methods for stereospecific synthesis of 9-cis olefins and retinoids. In one particular aspect, a cis olefin is generated via a lactol ring opening with complete retention of double bond configuration.

Description

DESCRIPTION
STEREOSPECIFIC SYNTHESIS OF POLYENE COMPOUNDS
Related Application
This application is a continuation-in-part of the application Serial No. 08/052,040 filed on April 21, 1993, whose entire disclosure is incorporated herein by reference.
Field Of The Invention
The present invention relates to the stereospecific synthesis of polyene compounds, such as eicosanoids and retinoids. In one particular aspect, a cis olefin is generated via a lactol ring opening with complete retention of double bond configuration.
Background Of The Invention
In many examples of natural products, an extended conjugated olefinic chain is present and important for biological effects. Many of the compounds within the arachidonic acid cascade (eicosanoids) are important modulators of inflammation. For example, leukotriene 34 has been detected in fluid from involved tissue in rheumatoid arthritis, gout, psoriasis and ulcerative colitis. (Bhattacherjee et al . , Ann . N. Y. Acad. Sci . , 524:307 (1984)). The absolute stereochemistry of the olefinic series is often an important feature of these compounds.
The retinoid members of the steroid/thyroid superfamily of receptors are responsive to compounds referred to as retinoids, which include retinoic acid, retinol (vitamin A) , and a series of natural and synthetic derivatives which have been found to exert profound effects on development and differentiation in a wide variety of systems. Novel members of the steroid/thyroid superfamily of receptors have been identified which are not responsive to retinoic acid, called retinoid X receptors. 9-o's-retinoic acid has been demonstrated to have affinity for retinoid X receptors (Heyman et al., Cell, 68:397 (1992)), and other retinoids having 9-10 cis olefin geometry have been found to selectively activate retinoid X receptors.
Therefore, it would be advantageous to selectively prepare retinoid and retinoid-like compounds with the 9-10 olefin bond in a cis-configuration, and to prepare other polyene compounds having the desired stereochemistry.
The literature has examples of the preparation of 9- 10 cis olefin retinoids, but none of which are specific in their construction of the 9-10 olefin bond. (See Robeson et al., ). Am. Chem. Soc., 77:4111 (1955) ; Matsui, βt al., J. Vitaminol., 4:178 (1958); Pat. No. DE 1068719 (1958); Aurell, et al., Tetra- hedron Lett., 31:5791 (1990). The stereoselective preparation of the 13-14 olefin bond has been reported. (Pattenden et al., J. Chem. Soc. (Q, 1984 (1968) ; Mayer eta/., Experientia, 34:1105 (1978) . Other information helpful in the understanding and practice of the present invention can be found in:
U.S. Pat. No. 3,006,939 (1961); Pat. No. DE 1050763
(1959); Pat. No. DE 1174769 (1964); Pat. No. DE 1068710
(1959) . The entire disclosures of the publications and refer¬ ences referred to above and hereafter in this specification are incorporated herein by reference.
Detailed Description Of The Invention
In accordance with the present invention, we have developed methods to prepare 9-cis retinoids and other polyene compounds with very high selectivity of all olefin bond-forming reactions. Specifically, we have developed methods to prepare a trans/cis diene acyclic carbon skeleton from a lactol ring (Scheme 1) , which can be used in the synthesis of cis-olefin containing natural or modified natural products and synthetically-manufactured analogs of such compounds. In a further aspect of the invention, we selectively prepare a trans/ trans diene acyclic carbon skeleton by a modified ittig coupling reaction (Scheme 2) , as shown below.
Scheme 1: Stereospecific Generatin of a E/Z Olefin Chain
Scheme 2: Stereospecific Generation of a E/E Olefin Chain
In the above process sequence, R1 represents a lower or branched alkyl having 1-12 carbons, or phenyl, and can be methyl only if R2 is hydrogen or a lower alkyl having 1- 8 carbons;
R2 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen, or R1 and R2 taken together form a phenyl, cyclohexyl, or cyclopentyl ring;
R3 represents a lower alkyl having 1-8 carbons, polyene compounds of the formula R1-CH=CH-C(R1) =CH- (E or Z orientation) , cycloalkyl, or aryl;
R4 represents hydrogen, a lower alkyl having 1-8 carbons, or a halogen; and R5 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen.
Together and in sequence, we have developed preferred methods to prepare 9 - cis retinoids in five steps with very high selectivity of all olefin bond-forming reactions. This sequence of steps is generally shown below:
In the above process sequence, R1 represents a lower or branched alkyl having 1-12 carbons, or phenyl, and can be methyl only if R2 is hydrogen or a lower alkyl having 1- 8 carbons;
R2 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen, or R1 and R2 taken together form a phenyl, cyclohexyl, or cyclopentyl ring or one of the following:
R3 represents a lower alkyl having 1-8 carbons, polyene compounds of the formula R1-CH=CH-C(R1)=CH- (E or Z orientation) , cycloalkyl, or aryl;
R4 represents hydrogen, a lower alkyl having 1-8 carbons, or a halogen;
Z, Z', Z", and Z'", each independently, represent C, S, 0, N, or a pharmaceutically acceptable salt, but not 0 or S if attached by a double bond to another such Z or if attached to another such Z which is 0 or S, and not N if attached by a single bond to another such Z which is N; and the dashed lines in the structures depict optional double bonds.
Additional substitutions are also possible for the terminal COOH group of acid VI and can be readily made by those of skill in the art. For example, instead of COOH the terminal group may be tetrazole, P03H, S03H, CHO, CH2OH, C0NH2, COSH, COOR9, COSR9, CONHR9, or COOW where R9 represents a lower alkyl having 1-4 carbons, phenyl, or q- hydroxyphenyl, q-bromophenyl, q-chlorophenyl, q- florophenyl, or q-idodophenyl, where q=2-4, and where is a pharmaceutically acceptable salt.
As used in this disclosure, pharmaceutically acceptable salts include but are not limited to: hydrochloric, hydrobromic, hydroiodic, hydrofluoric, sulfuric, citric, maleic, acetic, lactic, nicotinic, succinic, oxalic, phosphoric, malonic, salicylic, phenylacetic, stearic, pyridine, ammonium, piperazine, diethylamine, nicotinamide, formic, urea, sodium, potassium, calcium, magnesium, zinc, lithium, cinnamic, methylamino, methanesulfonic, picric, tartaric, tri- ethylamino, dimethylamino, and tris (hydroxymethyl)amino- methane. Additional pharmaceutically acceptable salts are known to those of skill in the art.
The preferred process sequence begins with the use of a commercially available aldehyde β-cyclocitral I and the well established Reformatsky reaction. (Dugger eta/., ]. Org. Chem., 45:1181 (1980) ; Gedye et al., Can. ). Chem., 53:1943 (1975) ; Cainelli eta/., J.C.S. Perkin I 1597 (1979)). This step constructs the 9-10 olefin bond in the desired cis-orientation, as shown (II) .
The second step consists of reduction of the lactone to a protected aldehyde (lactol) which is necessary for chain length extension. The reduction is achieved with 1 equivalent of diisobutylaluminum hydride and is sensitive toward work-up. We have found that the exclusion of water during the final purification of product greatly enhances the yield. Other reducing agents such as lithium aluminum hydride and sodium bis(2-methoxyethoxy)aluminum hydride can give the same product III but in diminished yield. The third step of this sequence involves a unique and novel lactol ring opening under the presence of acid to afford the aldehyde IV. This step constitutes a major advantage over existing syntheses of the aldehyde IV previously reported in the literature. The ring opening is very sensitive to the pKa of the acid, the concentration of the acid, the concentration of the reactant in the solvent, and the temperature of the reaction. The reaction can be run in chlorinated solvents (CHCL3, CH2CL2, C1CH2CH2C1) , apolar solvents (benzene, toluene) , or coordinating solvents (diethylether, tetrahydrofuran) . The choice of acids includes: para- toluene sulfonic acid, pyridinium hydrochloride, trichloro- or trifluoro-acetic acid, acetic acid, sulfuric acid, nitric acid, tartaric acid, oxalyic acid, and in particular hydrochloric acid. This third step can also be used to achieve the desired stereochemical orientation of olefin bonds for other polyene natural products, such as leukotriene B4, dehydroneral, etc., and synthetic analogs. Illustrative examples of such compounds are shown below:
Leukotriene B4
Dehydronerol
The fourth step of this sequence includes the selective formation of the C-ll and C-13 olefin bonds simultaneously. This reaction has been reported in the literature (Kryshtal et al., Izvestiya Akad. Nauk USSR, Seriya Khim., 11:2544 (1990)), but never with better than 5:1 ratio of 13-trans to 13-cis olefin formation. We have found that using a lithium coupled base in tetrahydrofuran in the presence of a coordinating solvent, such as dimethyl piperidine urea, allows the formation of the 11,13-trans- olefin bonds in a greater than 15:1 ratio. Other solvents, including diethyl ether, 1,4-dioxane, t-butyl- methyl ether, dimethyl formamide, dimethyl sulfoxide, methanol, ethanol, benzene, toluene, dichloromethane, chloroform, pyridine, and acetonitrile are less effective for overall yield of the desired 11,13-ditrans olefin product. Other bases (e.g., sodium hydride, sodium methoxide, sodium amide, potassium t-butoxide, potassium hydride, potassium di-isopropylamide, lithium diisopropylamide, lithium b/s-trimethylsilylamide) are less effective than n-butyl lithium. The reaction can be completed at -78°C or up to room temperature. The hydrolysis of the ester V to the acid VI is a standard saponification reaction. We have found that the reaction proceeds better in ethanol than ethanol due to the better solubility in the former solvent. One example of a VI compound is 9-c/s-retinoic acid. 11 - cis and 13 - cis retinoids and other related compounds, as illustrated below, can also be prepared using this process scheme.
The method of the current invention is shown by the following illustrative example.
Example
5,6-Dihydro-4-methyl-6- (2,6,6-trimethyl-l-cvclohexen- 1-yl) -2H-pyran-2-one (II, where R1 is methyl and R2 is hydrogen) : In a 300 ml round-bottomed flask fitted with a reflux condenser, nitrogen inlet, and 125 ml addition funnel was added 8.34 grams of zinc dust and 15 ml of dry tetrahydrofuran. The β-cyclocitral (18.5 grams) and bromo-ester (25.2 grams) were added to the addition funnel with 50 ml of dry tetrahydrofuran. The reactants were added dropwise following an initial addition of 5 ml to initiate the reaction. The rate of addition was adjusted to maintain a gentle reflux, with ca. 45 min for complete addition. The reaction solution was then heated to reflux for 30 minutes. After cooling to room temperature, 50 ml of saturated ammonium chloride solution was added and the solution stirred for 30 min. The reaction solution was worked up with addition of another 100 ml of saturated ammonium chloride solution to a 500 ml separatory funnel and dimethyl ether extraction (3 x 75 ml) . The combined organic layers were washed with brine and dried over MgS04. Concentration in vacuoproduced 28.7 g (100%). The product was dissolved in 150 ml of hot hexane and allowed to recrystallize with cooling. The white solid was filtered and collected to yield 22.5 grams of II (78.4%). XHNMR
(CDC13, 400 MHz); d (ppm) 5.82 (s, 1H) , 4.96 (dd, 13.4, 4.4 1H) , 2.88 (dd, 13.4, 18.5, 1H) , 2.16 (dd, 18.5, 3.4, 1H) , 1.98 (s, 3H) , 1.96 (m, 1H) , 1.75 (s, 3H) , 1.57-1.65 (m, 2H) , 1.42-1.50 (m, 2H) , 1.09 (s, 3H) , 0.97 (s, 3H) . IR
(KBr, cm"1): 2933, 1718, 1699, 1257.
5,6-Dihydro-4-methyl-6- (2,6,6-trimethyl-l-cvclohexen- 1-yl) -2H-pyran-2-ol (III, where R1 is methyl and R2 is hydrogen) : To 1.2 L of tetrahydrofuran (THF) was added the lactone (165 g) . The resulting solution was cooled in a -78°C bath and with constant stirring was added DIBAL (920 ml, 1.0 M in CH2C12) dropwise, never allowing the solution to warm above -40°C (2 h addition time) . After 15 minutes the reaction was complete, as evidenced by tic (Et20/Hexane; 40:60). To the cooled solution was added 500 ml of 10% H20/THF as a quenching solution. The solution was removed from the bath and allowed to warm to room temperature, while monitoring the rate of warming. After reaching ca. 10-15°C there was noticed a significant exotherm with the precipitation of salts. This exotherm was retarded by use of the cooling bath again. At this point, 100 g of Na2S04 was added and the resulting suspension was stirred for 0.5 hours. The solution was filtered through a bed of Celite, the bed washed with THF (2 x 500 mL) and the solution concentrated to yield an oil with solid ppt. The oil was slurred up in hexane (500 ml) and cooled to -20°C in the refrigerator. The first crop of solid material was 77 g. The filter cake was rinsed again with THF (2 x 500 ml) and concentrated to an oil with solid. Addition of hexane (300 ml) gave another 54 g of product for a total of 131 g (79%) . 1HNMR (CDC13, 400 MHz) : d (ppm) 5.54 (s, 1H) , 5.45 (s, 1H) , 4.65 (dd, 11.5, 4.0, 1H) , 2.71 (d, 4.0, 1H) , 2.48 (dd, 11.5, 17.0, 1H) , 1.97 (t, 6.5, 2H) , 1.81 (m, 2H) , 1.79 (s, 3H) , 1.76 (s, 3H) 1.55-1.63 ( , 2H) , 1.41-1.53 (m, 2H) . 1.11 (s, 3H) , 0.97 (S, 3H) . IR (KBr, cm"1) : 3377, 2935, 2908, 1037. mp 147-149°C.
(2Z.4£) -3-Methyl-5- (2,6, 6-trimethylcyclohexen-l-yl) - 2 ,4-pentadieneal (IV, where R1 is methyl and R2 is hydrogen) : To 1 L of 1,2-dichlorethane was added lactol (119 grams) and 100 μL of concentrated HCl (38%) with constant stirring at room temperature. The reaction was heated to bring the solution to reflux and proceeds very quickly. The reaction is monitored by tic (40% Dimethyl ether/Hexane) . After 35 m the reaction was quenched with 400 mL of saturated NaHC03. After separation of layers the resulting red organic layer was dried over MgS02 and concentrated in vacuo to yield the desired aldehyde as a red oil. This oil was taken up in 500 ml of hexane and 120 g of silica gel (230-400 mesh) added. The solution was filtered, rinsed with another 500 ml of hexane, and concentrated to an orange oil (100.2 grams, 91%) . An alternate procedure for production of the aldehyde is as follows: To a solution of 250 ml of 1,2-dichloroethane was added 30 g of the lactol and 125 ml of IN HCl solution. The two phase solution was heated to 40°C and monitored by TLC. The reaction was found to be complete after 12.5 hours. The reaction was quenched by the separation of layers and 500 ml of saturated Na2C03 carefully added to the organic layer with stirring. The aqueous layer was washed with two 100 ml portions of dichloromethane and the collective organic layers washed once with brine. The organic solution was then dried over K2C03 (anhydrous) and concentrated in vacuo to. afford a red-orange oil. The crude product was diluted with hexanes (125 ml) and to this solution was added silica gel (30 g) . The slurry was filtered and the silica rinsed until no more color came through the filter. The solution was concentrated in vacuo to afford 26 grams (94%) of clean product as a yellow-orange oil. ^NMR (CDC13, 400
MHz) : d (ppm) 10.16 (d, 8.0, 1H) , 7.08 (d, 16.0, 1H) , 6.63 (d, 15.0, 1H) , 5.86 (d, 8.0, 1H) , 2.12 (s, 3H) , 2.05
(t, 6.0, 2H) , 1.75 (s, 3H) , 1.57-1.75 (m, 2H) , 1.40-1.53
(m, 2H) , 1.05 (s, 6H) . IR (film, cm"1) : 2930, 1667.
Ethyl 3 , 7-dimethyl-9- (2,6, 6-trimethylcvclohexen-l- yl) -2-trans-4-trans-6-c/5-8-trans-nonatetraenoate (V, where R1 and R3 are methyl and R2 is hydrogen) : A solution of 233 ml of tetrahydrofuran, 276 ml of 2, 6-dimethylpiperidineurea and the phosphonate (109.4 grams) was cooled to -30°C by use of a C02/acetone bath. Into this solution was added n-Buli (180 ml, 2.3 M in hexane), dropwise. The reaction solution was cooled and allowed to stir at -78°C for 0.25 hour before the aldehyde (75.4 g, 345 mmol) was added in 50 ml of tetrahydrofuran. The reaction was stirred at -78°C for another 0.5 hours, then quenched by the addition of 200 ml of saturated ammonium chloride solution. The aqueous solution was extracted with diethylether (3 x 500 ml) , and the combined organic extracts washed with brine and dried over magnesium sulfate. The crude reaction products (primarily 9 -cis-13 -trans retinoate and 9, 13-di-c/s-retinoate) were collected by concentration in vacuo to give a red-orange oil. The crude ester was taken up in 100 ml of 20% Et20/Hexane and filtered through 500 g of silica gel (230-400 mesh) which was rinsed with another 700 ml of eluent . The ester was concentrated to an orange oil (100.4 g, 93%) which looked very clean by NMR. The 13 E/Z ratio was > 15:1. 1HNMR (CDC13, 400 MHz) ; d (ppm) 7.08 (dd, 15, 11.3, 1H) , 6.65 (d, 16, 1H) , 6.29 (d, 15, 1H) , 6.23 (d, 15, 1H) , 6.06 (d, 11.3, 1H) , 5.77 (s, 1H) , 4.17 (q, 7, 2H) , 2.34 (s, 3H) , 2.05 (t, 7, 2H) , 2.00 (m, 3H) . 1.75 (s, 3H) , 1.61-1.68 (m, 2H) , 146-151 (m, 2H) , 1.29 (t, 7, 3H) , 104 (s, 6H) . IR (film, cm"1) : 2928, 1709. 3 , 7-dimethyl-9- (2,6, 6-trimethylcyclohexen-l-yl) -2- trans-4-trans-6-cis-8-trans-nonatetraenoic acid (VI, where R1 and R3 are methyl and R2 is hydrogen) : The ester (100.4 grams) was slurred in 700 ml of ethanol. To this solution was added 700 ml of 14 wt% NaOH/water (100 g NaOH) and the solution heated to 60°C for 1 hour. Following the hydrolysis by TLC (25% ethyl acetate/hexane) , one could see that the hydrolysis was incomplete. The solution was heated for another 2 hours and at this time appeared to be complete (TLC) . The solution was allowed to cool, extracted with hexane (3 x 250 ml) , and then cooled to 0°C, at which point it was acidified with 3 N HCl to pH 2. The yellow-orange solid that precipitated from the aqueous solution was filtered, rinsed with water (2 liters) , and then dissolved up in 1 liter THF/Et20 (3:1) . The organic solution was washed with brine and dried over magnesium sulfate. Concentration in vacuo gave 83.3 g of a light yellow solid (80.3% from aldehyde) . 1HNMR (CDC13, 400 MHz) : d (ppm) 7.20 (dd, 11.0, 15.0, 1H) , 6.65 (d, 16.0, 1H) , 6.28 (d, 16.0, 1H) , 6.25 (d, 15.0, 1H) , 6.06 (d, 11.0, 1H) , 5.80 (s, 1H) , 2.35 (s, 3H) , 2.05 (t, 6.6, 2H) , 2.01 (s, 3H) , 1.75 (s, 3H) , 1.64 (m, 2H) , 1.49 (m, 2H) . 1.04 (s, 6H) . IR (KBr, cm"1) : 2914, 1670, 1583. mp 188- 190°C UV (MeOH) : λ max=343 (37,800) . Analysis Theoretical C:79.95, H: 9.39, O: 10.65 Found C:79.97, H:9.38, 0:10.66.
While the preferred embodiments have been described and illustrated, various substitutions and modifications may be made thereto without departing from the scope of the invention. Accordingly, it is to be understood that the present invention has been described by way of illustration and not limitation.

Claims

Claims 1, A method for producing a cis-olefin, comprising: combining a lactol of the formula
with acid and solvent reactants; heating said reactants; and quenching and separating the resulting aldehyde product having the formula
wherein R1 represents a lower or branched alkyl having 1-12 carbons, or phenyl, and can be methyl only if R2 is a hydrogen or a lower alkyl having 1-8 carbons,
R2 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen, or R1 and R2 taken together form a phenyl, cyclohexyl, or cyclopentyl ring,
R3 represents a lower alkyl having 1-8 carbons, polyene compounds of the formula R1-CH=CH-C(R1)=CH- (E or Z orientation) , cycloalkyl, or aryl, and
R5 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen.
2. The method of claim 1 wherein R1 is methyl, R2 is hydrogen, R3 is 2,6,6-trimethylcyclohexen-l-yl, and Rs is hydrogen.
3. The method of claim 1 wherein said acid is selected from the group comprising para-toluene sulfonic acid, pyridinium hydrochloride, trichloro- or trifluoro- acetic acid, acetic acid, sulfuric acid, nitric acid, tartaric acid, oxalyic acid, and hydrochloric acid.
4. The method of claim 1 wherein said solvent is selected from the group comprising chlorinated solvents, apolar solvents, or coordinating solvents.
5. A method of selective formation of C-ll and C-13 olefin bonds, comprising: combining tetrahydrofuran and dimethyl piperidine urea to form a solution; adding to the solution a lithium-coupled base; adding to the solution an aldehyde of the formula R3CH0; and extracting and concentrating the ester reaction product, said ester having the formula
and wherein R2 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen,
R3 represents a lower alkyl having 1-8 carbons, polyene compounds of the formula R1-CH=CH-C(R1) =CH- (B or Z orientation) , cycloalkyl, or aryl, and R1 represents a lower or branched alkyl having 1-12 carbons or phenyl, and
R4 represents hydrogen, a lower alkyl having 1-8 carbons, or halogen.
6. The method of claim 5 wherein R1 is methyl, R2 is hydrogen, R3 is 1- (2-methyl-1, 3-butadien-4-yl) -2, 6, 6- trimethylcyclohexene, and R4 is methyl.
EP94915855A 1993-04-21 1994-04-21 Stereospecific synthesis of polyene compounds Ceased EP0695285A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP97122793A EP0839788A1 (en) 1993-04-21 1994-04-21 Stereospecific synthesis of polyene compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5204093A 1993-04-21 1993-04-21
US52040 1993-04-21
PCT/US1994/004440 WO1994024082A1 (en) 1993-04-21 1994-04-21 Stereospecific synthesis of polyene compounds

Publications (2)

Publication Number Publication Date
EP0695285A1 true EP0695285A1 (en) 1996-02-07
EP0695285A4 EP0695285A4 (en) 1996-05-01

Family

ID=21975045

Family Applications (2)

Application Number Title Priority Date Filing Date
EP97122793A Withdrawn EP0839788A1 (en) 1993-04-21 1994-04-21 Stereospecific synthesis of polyene compounds
EP94915855A Ceased EP0695285A4 (en) 1993-04-21 1994-04-21 Stereospecific synthesis of polyene compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP97122793A Withdrawn EP0839788A1 (en) 1993-04-21 1994-04-21 Stereospecific synthesis of polyene compounds

Country Status (5)

Country Link
EP (2) EP0839788A1 (en)
JP (1) JPH08509229A (en)
AU (1) AU671752B2 (en)
CA (1) CA2160240A1 (en)
WO (1) WO1994024082A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2603095A (en) * 1994-05-27 1995-12-21 Ligand Pharmaceuticals Incorporated Methods for the synthesis of 9-(cis) retinoids and their novel intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997529A (en) * 1975-07-09 1976-12-14 Hoffmann-La Roche Inc. Intermediate compounds for the preparation of polyene aldehydes
US4523042A (en) * 1983-07-29 1985-06-11 Usv Pharmaceutical Derivatives of alpha-alkyl polyolefinic carboxylic acid useful in the treatment of psoriasis
FR2655341B1 (en) * 1989-12-01 1992-02-21 Rhone Poulenc Sante DIHYDROPYRANIC DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE.
US5250710A (en) * 1989-12-01 1993-10-05 Rhone-Poulenc Nutrition Animale Dihydropyran derivatives, processes for preparation and use
US5094783A (en) * 1990-06-29 1992-03-10 Uab Research Foundation Retinoid compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO9424082A1 *

Also Published As

Publication number Publication date
JPH08509229A (en) 1996-10-01
CA2160240A1 (en) 1994-10-27
EP0695285A4 (en) 1996-05-01
EP0839788A1 (en) 1998-05-06
AU6772194A (en) 1994-11-08
WO1994024082A1 (en) 1994-10-27
AU671752B2 (en) 1996-09-05

Similar Documents

Publication Publication Date Title
EP1626045A1 (en) Processes for producing 3-substituted 2-chloro-5-fluoropyridine or salt thereof
DK175169B1 (en) Carotenoid intermediates, processes for their preparation and use of the intermediates in the preparation of carotenoids
EP1328506B1 (en) Intermediates for use in retinoid synthesis
JP2001513113A (en) Aryl- and heteroarylcyclohexenyl-substituted alkenes having biological activity of the retinoid agonist, antagonist or inverse agonist type
Ikeda et al. Facile routes to natural acyclic polyenes syntheses of spilanthol and trail pheromone for termite
US5567855A (en) Methods for stereospecific synthesis of polyene aldehydes
WO2012155796A1 (en) Stereospecific synthesis process for tretinoin compounds
WO1994024082A1 (en) Stereospecific synthesis of polyene compounds
JPH08311021A (en) Production of beta-carotene product with high 9(z) content
JP4563997B2 (en) Method for preparing 9-cis retinoic acid
US4543417A (en) ω,ω-Diacyloxy-2,6-dimethyl-octatrienoates and -octatrienals, their preparation and their use for the synthesis of terpene compounds
JPH10501232A (en) Method for synthesizing 9-cis retinoid and novel intermediate thereof
CN106467464B (en) (E) -2-isopropyl-5-methyl-3, 5-hexadienoic acid ester compound and production method and application thereof
DE60105729T2 (en) Process for the preparation of retinol and intermediates for this process
Davalian et al. Synthesis of 7, 8-epoxy-7, 8-dihydroretinoids
JPH0425263B2 (en)
MXPA96004879A (en) Methods for the synthesis of retinoids 9-cis and its intermediaries novedo
Addie et al. 1, 3-Dienes from ketones via the Shapiro reaction
KR100208427B1 (en) A process for producing d, l, -3-methyl-cyclopentadecan-1-one
JP3727428B2 (en) Process for producing 11-cis retinal and synthetic intermediate useful for the process
KR20030076243A (en) Novel sulfone derivatives and process for producing these
DE2642006A1 (en) METHOD FOR PRODUCING 1,1-DICHLORO-1,3-BUTADIENE
SK1612002A3 (en) Process for the preparation of isotretinoin
EP0019132A1 (en) Process for the preparation of alpha-halogen cyclobutanones
JP2003176263A (en) Hydroxysulfone derivative and method for producing the same

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951121

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960319

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19970224

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19990830